Search results for: BAFF (B cell activating factor), Human Antibody
#31518874 // Save this To Up
A novel human anti-BAFF neutralizing monoclonal antibody derived from in vitro immunization.B-cell activating factor (BAFF) plays a key role in the normal regulation of B cell development and immune response. Its abnormal expression level is accompanied by the occurrence of various autoimmune diseases. Therefore, BAFF is an effective target for the treatment of such diseases. Here, we report a new anti-BAFF monoclonal antibody. Based on improved in vitro immunization method, we used a recombinant BAFF containing unnatural amino acid p-nitro-phenylalanine (pNOPhe) as an antigen to trigger immune response in vitro. The plasma cells were sorted by flow cytometry (FACS), and the antibody library was constructed based on the sorted plasma cells. The high affinity antigen-binding fragments were panned by phage display technology, and finally the anti-BAFF human IgG was obtained. The antibody demonstrated its ability to neutralize BAFF effectively both in vitro and in vivo. We propose that this novel full-length human anti-BAFF monoclonal antibody is a promising therapeutic candidate for the treatment of autoimmune diseases.
2276 related Products with: A novel human anti-BAFF neutralizing monoclonal antibody derived from in vitro immunization.Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon Monoclonal anti-human CD5 Mouse Anti-Insulin(1D4 ) MOUSE ANTI HUMAN DESMIN-M Anti-human C1 Esterase In Anti-Human, Mouse Monoclo Mouse Monoclonal Antibody MOUSE ANTI HUMAN CD15, Pr Mouse Monoclonal Antibody Anti AGO2 Human, Monoclon anti CD54 IgG2b k monoclo
#31464677 // Save this To Up
Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome.Primary Sjögren's syndrome (pSS) is an autoimmune connective tissue disease characterised by an enhanced lymphoproliferative status, with a greater risk of hesitating in malignant lymphoma. The pathological hallmark of pSS is the mucosa-associated lymphoid tissue (MALT) arising in chronically inflamed tissues, mainly in salivary glands (SG), where inflammation, autoimmunity and lymphoproliferation coexist. In the microenvironment of MALT, the B lymphocyte activating factor (BAFF or BLys) is one of the main actors contributing to B cell survival and hyperactivity in pSS. Due to such a lymphoproliferative background, targeting directly and/or indirectly B lymphocytes has become a cornerstone of developing therapeutic strategies for pSS. The simultaneous and direct targeting of the BAFF axis and of B cells represents a promising new treatment approach for pSS and other immune-mediated diseases, but only investigational at present. Immunobiological evidences support a sequential scheme of administration with belimumab preceding rituximab, aiming to firstly target the microenvironmental BAFF to improve the success of the subsequent depleting treatment in the MALT pathologic tissue with rituximab. In a real pSS case, the sequential therapy with belimumab alone followed by rituximab alone successfully led to a long-term clinical remission of lymphoma and cryoglobulinaemic vasculitis, together with the persistent normalization of B cell hyperactivity and the disappearance of persistent SG swelling and cryoglobulinaemia, which are strong predictors of lymphoma in pSS. Hopefully, further trials will assess if improvement in B-cell targeting will lead to the decrease in SG lymphoid infiltrate as well as to a possible reduction of lymphoma development in pSS.
1195 related Products with: Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome.Anti-Mouse B220 (B cell s MOUSE ANTI BORRELIA BURGD Mouse Anti Pig B Cell Sub MOUSE ANTI BOVINE ROTAVIR Mouse Anti-Pig B Cell Sub Anti Mouse B220 (B cell s RABBIT ANTI GSK3 BETA (pS Anti C Reactive Protein A Rabbit Anti-SDH S6PDH Pol Rabbit Anti-Phospho-SHP2 Ovary cancer tissue array Anti-Bacillus spores Unco
#31444033 // Save this To Up
Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.Comorbidities including subclinical atherosclerosis, neuropsychological aberrations and lymphoproliferation represent a major burden among patients with systemic autoimmune diseases; they occur either as a result of intrinsic disease related characteristics including therapeutic interventions or traditional risk factors similar to those observed in general population. Soluble molecules recently shown to contribute to subclinical atherosclerosis in the context of systemic lupus erythematosus (SLE) include among others B-cell activating factor (BAFF), hyperhomocysteinemia, parathormone (PTH) levels and autoantibodies against oxidized lipids. Variations of the 5, 10- methylenetetrahydrofolate reductase (MTHFR) gene -the main genetic determinant of hyperhomocystenemia in humans-as well the interferon regulatory factor-8 (IRF8), FcγRIIA and BAFF genes have been all linked to subclinical atherosclerosis in SLE. BAFF variants have been also found to confer increased risk for subclinical atherosclerosis and lymphoma development in Sjogren's syndrome (SS) patients. Other genes shown to be implicated in SS lymphoproliferation include genes involved a. in inflammatory responses such as the NFκB regulator Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) and the Leukocyte immunoglobulin-like receptor A3 (LILRA3) immunoreceptor, b. B cell activation and signaling (BAFF/BAFF-receptor), c. type I IFN pathway such as three-prime repair exonuclease 1 (TREX1), d. epigenetic processes including DNA methylation (MTHFR rs1801133, 677T allele) and e. genomic instability (MTHFR rs1801131, 1298C allele). Emerging soluble biomarkers for SS related lymphoma include mediators of B cell growth and germinal center formation such as BAFF, FMS-like tyrosine kinase 3 ligand (Flt-3L) and CXCL13 as well as inflammatory contributors such as inteleukin (IL)-17, IL-18, ASC, LILRA3 and the extracellular lipoprotein-associated phospholipase A2 (Lp-PLA2). In regard to fatigue and neuropsychologic features in the setting of SS, contributing factors such as BAFF variants, antibodies against neuropeptides, proteins involved in nervous system function as well as inflammatory cytokines have been reported.
2508 related Products with: Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.Octyl â D 1 thioglucopyr Human soluble interleukin rHIV gp41, soluble Antige rHIV gp36, soluble Antige Human soluble interleukin includes 10 x reaction bu MAX & SMAD3 Protein Prote Stomach adenocarcinoma ti Recombinant Mouse Interle 1-Acetyl-3-indoxyl Sulfat Goat Anti-Human ARMET, (i Lung cancer tissue array,
#31423896 // Save this To Up
Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus.We evaluated the effects of the B-cell activating factor (BAFF)-targeting antibody Belimumab on human nonmemory B-cell pools. Human B-cell pools were identified using surface markers adapted from mouse studies that specifically assessed reductions in immature B cells due to BAFF depletion. Patients with systemic lupus erythematosus (SLE) have high levels of both BAFF and immature B cells. Mechanistic mouse studies provide a framework for understanding human responses to therapies that target B cells.
2617 related Products with: Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus.Lung small cell carcinoma Pressure Injection Cell w CELLKINES INTERLEUKIN 2 ( Kidney clear cell carcino Stat3 Peptide Inhibitor, Mouse Anti Pig B Cell Sub Cultrex 96 Well Laminin I GLP 2 ELISA Kit, Rat Prog Cultrex96 Well 3D BME Cel Rabbit Anti-Cell death in p53 Luciferase Reporter R Esophageal squamous cell
#31231554 // Save this To Up
Therapeutic effects of a novel BAFF blocker on arthritis.B-cell targeted therapy is effective for autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis (RA), although there are setbacks in RA clinical trials. In this study, we designed a novel B-cell activating factor (BAFF) antagonist: BAFF-Trap, a recombinant glycoprotein with BAFF-binding domains of two BAFF receptors (TACI and Br3) linked to Fc domain of human IgG1. Unlike TACI-Fc, BAFF-Trap bound BAFF but not APRIL (a proliferation-inducing ligand), and significantly suppressed the development of collagen-induced arthritis and adjuvant-induced arthritis. Furthermore, BAFF-Trap inhibited proinflammatory cytokine expression, ameliorated joint damage and suppressed B- and T-cell activation. BAFF-Trap reduced dendritic cells in joints, and increased regulatory T cell, regulatory B-cell, and M2 macrophage. The function of BAFF-Trap was related to inhibition of canonical and noncanonical NF-κB activation. Thus, BAFF-Trap may be a valuable agent for the effective treatment of RA.
Normal mouse multiple org Oncocytoma tissue array, BAFF-R Antibody Rat monoclonal anti mouse Anti BAFF produced in rab BAFF (B cell activating f FDA Standard Frozen Tissu Benz[j]aceanthrylen-2(1H) BAFF BLyS Thank, C-Termin FDA Standard Frozen Tissu Normal rat multiple organ Rabbit Anti-FGF3 Oncogene
#31181988 // Save this To Up
Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.We describe a bispecific dual-antagonist antibody against human B cell activating factor (BAFF) and interleukin 17A (IL-17). An anti-IL-17 single-chain variable fragment (scFv) derived from ixekizumab (Taltz®) was fused via a glycine-rich linker to anti-BAFF tabalumab. The IgG-scFv bound both BAFF and IL-17 simultaneously with identical stoichiometry as the parental mAbs. Stability studies of the initial IgG-scFv revealed chemical degradation and aggregation not observed in either parental antibody. The anti-IL-17 scFv showed a high melting temperature () by differential scanning calorimetry (73.1°C), but also concentration-dependent, initially reversible, protein self-association. To engineer scFv stability, three parallel approaches were taken: labile complementary-determining region (CDR) residues were replaced by stable, affinity-neutral amino acids, CDR charge distribution was balanced, and a H44-L100 interface disulfide bond was introduced. The of the disulfide-stabilized scFv was largely unperturbed, yet it remained monodispersed at high protein concentration. Fluorescent dye binding titrations indicated reduced solvent exposure of hydrophobic residues and decreased proteolytic susceptibility was observed, both indicative of enhanced conformational stability. Superimposition of the H44-L100 scFv (PDB id: 6NOU) and ixekizumab antigen-binding fragment (PDB id: 6NOV) crystal structures revealed nearly identical orientation of the frameworks and CDR loops. The stabilized bispecific molecule LY3090106 (tibulizumab) potently antagonized both BAFF and IL-17 in cell-based and mouse models. In cynomolgus monkey, it suppressed B cell development and survival and remained functionally intact in circulation, with a prolonged half-life. In summary, we engineered a potent bispecific antibody targeting two key cytokines involved in human autoimmunity amenable to clinical development.
2794 related Products with: Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.Anti-daf-2(Abnormal dauer Anti-BAFF produced in rab Androgen Receptor (Phosph CRC3 CD3 bispecific anti FDA Standard Frozen Tissu BAFF-R Antibody Normal mouse multiple org Androgen Receptor (Ab 650 Anti 3 DG imidazolone Mon Androgen Receptor Antibod RABBIT ANTI GSK3 BETA (pS CRC3 CD3 (bispecific) Cl
#31173604 // Save this To Up
Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c+ B-cells in the genital tract.BLyS/BAFF is recognized for its role in B-cell ontogenesis, as well as cell fate decision towards the first-line/innate marginal zone (MZ) B-cell pool. Excess BLyS/BAFF is associated with hyperglobulinemia and increased frequencies of activated precursor-like MZ B-cells. Herein, we show that HIV highly-exposed seronegative (HESN) commercial sex workers (CSWs) had lower soluble BLyS/BAFF levels and relative frequencies of BLyS/BAFF expressing cells in their genital mucosa when compared to those from HIV-infected CSWs and HIV-uninfected non-CSWs. Furthermore, we identified genital innate and/or marginal zone (MZ)-like CD1c+ B-cells that naturally bind to fully glycosylated gp120, which frequencies were lower in HESNs when compared to HIV-infected CSWs and HIV-uninfected non-CSWs. Although genital levels of total IgA were similar between groups, HESNs had lower levels of total IgG1 and IgG3. Interestingly, HIV-gp41 reactive IgG1 were found in some HESNs. Low genital levels of BLyS/BAFF observed in HESNs may allow for controlled first-line responses, contributing to natural immunity to HIV.
2620 related Products with: Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c+ B-cells in the genital tract.FDA Standard Frozen Tissu Mouse AntiHIV1 integrase FDA Standard Frozen Tissu HIV1 integrase antibody, FDA Standard Frozen Tissu FDA Standard Frozen Tissu Thermal Shaker with cooli Rabbit Anti-APIP Apaf1 In Anti AGO2 Mouse, Monoclon Rabbit Anti-Cell death in Native Influenza HA (A So Rabbit Anti-Integrin alph
#30957421 // Save this To Up
Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome.Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. It is well known that upper respiratory tract infections, particularly acute tonsillitis, often worsen IgAN. Recent many clinical studies clearly show that tonsillectomy with steroid pulse therapy is the effective treatments for IgAN patients. Recently, the immunological evidence of association between tonsil and IgAN has been reported.
2108 related Products with: Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome.OxiSelect™ Cellular UV- Cell Meter™ Intracellul Anti AGO2 Human, Monoclon Caspase 3 Inhibitor Drug Cell Meter™ Fluorimetri Human Macrophage Inflamma EMAP II Inhibitor Z ASTD Amplite™ Fluorimetric H Alkaline Phospatase (ALP) Cultrex 96 Well Laminin I CETP Inhibitor Drug Scree EpiQuik Superoxide Dism
#30849450 // Save this To Up
B cells in chronic graft-versus-host disease.Allogeneic hematopoietic stem cell transplantation (alloHCT) is the definitive therapy for numerous otherwise incurable hematologic malignancies and non-malignant diseases. The genetic disparity between donor and recipient both underpins therapeutic effects and confers donor immune system-mediated damage in the recipient, called graft-versus-host disease (GVHD). Chronic GVHD (cGVHD) is a major cause of late post-transplant morbidity and mortality. B cells have a substantiated role in cGVHD pathogenesis, as first demonstrated by clinical response to the anti-CD20 monoclonal antibody, rituximab. Initiation of CD20 blockade is met at times with limited therapeutic success that has been associated with altered peripheral B cell homeostasis and excess B Cell Activating Factor of the TNF family (BAFF). Increased BAFF to B cell ratios are associated with the presence of circulating, constitutively activated B cells in patients with cGVHD. These cGVHD patient B cells have increased survival capacity and signal through both BAFF-associated and B Cell Receptor (BCR) signaling pathways. Proximal BCR signaling molecules, Syk and BTK, appear to be hyper-activated in cGVHD B cells and can be targeted with small molecule inhibitors. Murine studies have confirmed roles for Syk and BTK in development of cGVHD. Emerging evidence has prompted investigation of several small molecule inhibitors in an attempt to restore B cell homeostasis and potentially target rare, pathologic B cell populations.
Anti 3 DG imidazolone Mon Beta Amyloid (40) ELISA K Breast disease spectrum t MarkerGeneTM in vivo lacZ Nile Red, A lipophilic dy Leptin ELISA Kit, Rat Lep Beta Amyloid (1 40) ELISA anti-Diazepam Binding Inh Octyl â D 1 thioglucopyr Beta Amyloid (42) ELISA K Breast disease spectrum t anti-Diazepam Binding Inh
#30766889 // Save this To Up
Association between B Cell Growth Factors and Primary Sjögren's Syndrome-Related Autoantibodies in Patients with Non-Hodgkin's Lymphoma.Despite the overall success of using R-CHOP for the care for non-Hodgkin's lymphoma patients, it is clear that the disease is quite complex and new insight is needed to further stratify the patient for a better personized treatment. In current study, based on previous studies from animal model, new panels combining well-established cytokine (BAFF) and autoantibodies (anti-SSA/Ro) with newly identified cytokine (IL14) and autoantibodies (TSA) were used to evaluate the association between B cell growth factor and Sjögren's related autoantibodies in NHL patients. The result clearly indicates that there was a unique difference between BAFF and IL14 in association with autoantibodies. While serum BAFF was negatively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in GI lymphoma patient, IL14 was positively associated with the presence of both traditional anti-SSA/Ro and novel TSA antibodies in non-GI lymphoma patient. Long-term follow-ups on these patients and evaluation of their response to the R-CHOP treatment and recurrence rate will be very interesting. Our result provides a solid evidence to support using novel diagnostic panel to better stratify the NHL patients.
1688 related Products with: Association between B Cell Growth Factors and Primary Sjögren's Syndrome-Related Autoantibodies in Patients with Non-Hodgkin's Lymphoma.Nile Red, A lipophilic dy MarkerGeneTM Live Cell Lu MarkerGeneTM in vivo lacZ Leptin ELISA Kit, Rat Lep Biocidal ZF, spray disinf Biocidal ZF, spray disinf Primary antibody DRAK2 A Octyl â D 1 thioglucopyr Biocidal ZF, spray disinf Breast carcinoma tissue a Sheep Red Blood Cells, Pa Beta Secretase Inhibitor
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia